Opioid substitution therapy (ost) models of programme design and implementation
This document discusses opioid substitution therapy (OST) models of program design and implementation. It covers:
1. OST can be delivered in various settings like specialized clinics, hospitals, primary care, and communities. Delivery models include low threshold services to reduce barriers.
2. OST provides benefits as both a drug treatment for opioid dependence as well as for HIV prevention by reducing risky injection behaviors. Evidence shows methadone and buprenorphine maintenance therapy reduces opioid use and HIV transmission.
3. Integrating OST into HIV care improves adherence to antiretroviral therapy and engagement in care, while decreasing opioid use. Studies demonstrate the effectiveness of OST, especially methadone, in reducing HIV incidence.
Introduction to Opioid Substitution Therapy (OST) with an outline covering its models, effectiveness in drug treatment, and HIV prevention.
Description of different OST implementations: specialized clinics, hospitals, primary care, community, and custodial settings. Emphasis on low-threshold services.
Examples of OST in various countries: MMT in North America, Iran, Australia, and Asia; discussing scaling and integration in multiple regions.
Insights into community-based OST clinics in Chennai and Delhi, focusing on their implementation and service delivery.
The role of OST in prisons to reduce HIV transmission and support reintegration post-release, along with perspectives from Malaysian inmates.
Examination of OST for drug treatment versus HIV prevention, stressing methadone and buprenorphine effectiveness and benefits on HIV risk reduction.
Models of integrated OST services with emphasis on co-located care, psychosocial support, and the benefits of integrating substance use and medical care.
Identification of critical gaps in OST implementation amid resource-poor settings, focusing on adoption challenges and service linkages.
Summarization of OST effectiveness for opioid dependency, highlighting its potential to prevent HIV and the need for integrated services through collaboration.
Opioid substitution therapy (ost) models of programme design and implementation
1.
Opioid Substitution Therapy(OST):
Models of programme design and
implementation
Dr. M. Suresh Kumar MD DPM MPH
Consultant Psychiatrist
National CME: “Opioid Substitution Therapy: Policy and Practice”
Organised by NDDTC & AIIMS
New Delhi
April 18 2015Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
2.
Outline of presentation
1.OST in various settings and models of OST
2. OST as drug treatment vs OST as HIV prevention
3. Integrated OST services
4. Key gaps in OST program implementation
5. Summary
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
3.
1. OST INVARIOUS SETTINGS AND
MODELS OF OST
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
4.
OST in varioussettings
OST in specialised exclusive clinics
OST in hospitals
OST in drug dependence treatment clinics
OST in primary care settings
OST in community settings
OST in custodial settings
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
5.
OST in varioussettings
OST in hospitals
Department of Psychiatry
Department of General Medicine
OST in primary care settings
OST in primary health care settings
OST delivery through Pharmacies
OST in community settings
Government sponsored OST Clinics
NGO run OST Clinics
With Outreach Programs
With Peer Support
OST in custodial settings
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
6.
“Everyone deserves services
nomatter what”
Client centeredness
Low threshold services
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
7.
Low threshold OST
Disagreement between professional groups and programs on
definition of ‘low threshold’ OST
Abstinence from opioids and other drugs is not the treatment goal
High involvement of GPs and community health providers
Prescription of buprenorphine or slow release morphine
Reduce barriers for admission
Facilitate treatment retention
Strike et al, Int J Drug Policy 2013; 24(6):e51-6
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
8.
Facilitators of OST
Government sponsorship
No dispensing fee
Attractive to poor opioid dependent clients
Mobile units
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
9.
MMT in NorthAmerica
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
10.
Methadone: IRAN
Presented atthe national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
11.
MMT, Specialized clinic:Iran
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
12.
MMT, General hospital:Iran
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
13.
OST Clinic: Melbourne,Australia
WHO Jakarta
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
Community MMT Clinic:China
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
16.
MMT Clinics inChina
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
17.
OST in Asia
Methadone scaling up in:
China, Malaysia, Indonesia
Methadone established in:
Hong Kong, Thailand, Myanmar, Vietnam, Cambodia
Nepal, Bangladesh, Afghanistan, Maldives
Buprenorphine substitution in:
India
Malaysia
Detoxification using buprenorphine in Indonesia, Malaysia, India,
China, Myanmar
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
18.
Models of deliveryin South Asia
Model Bangladesh India Maldives Nepal
Drug used Methadone Buprenorphine
Methadone
Methadone Methadone
Beneficiaries PWID PWID People with
Opioid
dependence
PWID
Location GO run
hospital
NGO run TIs
GO-NGO
Model
Govt Dept of
Psychiatry,
Medical
College
Urine testing No No Random urine
screen
No
Rao et al, Bull World Health Organ 2013; 91:150-53
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
19.
OST in Asia
CountryEstimated no. of
PWID
No. of OST sites
in 2008
OST
in prison
Est. no. of PWID
covered by OST in
2008
China 1,800,000–
2,900,000
531 159,439
Indonesia 190,460–247,800 35 4 3300
India 106,518–223,121 47 1 4600
Malaysia 170,000–240,000 68 4 22000
Maldives 400–500 1 45
Myanmar 60,000–90,000 7 500
Nepal 28,000 2 192
Thailand 160,528 147 4000-5000
Viet Nam 135,305 6 1484
Adapted from: Chatterjee & Sharma / International Journal of Drug Policy 21 (2010) 134–136Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
20.
OST Scale-up inIndia (March 2014)
29
104
147
94
32
175
350
250
0
50
100
150
200
250
300
350
400
No of states
with OST
No of Districts
with OST
Services
No of OST
Centres
No of OST
centres with
Govt
Current Status
Targets
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
21.
Community based OSTClinic: Chennai
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
22.
Community based OSTClinic: Delhi,
India
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
23.
Implementation of OSTwithin
prison
OST reduces HIV transmission within prisons
It serves as a conduit to care after release from prison
It reduces the adverse consequences of injection drug
use, including overdose both within prison and after
release
Springer, 2010. Addiction, 105, 224–225Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
24.
MMT in PrisonMalaysia
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
25.
OST in prisons:Malaysia
Attitudes of prisoners to MMT
Secondary HIV prevention among prisoners in Malaysia
is crucial to reduce community HIV transmission after
release
Half of the surveyed HIV+ prisoners believed that OST
would be helpful, only a third said they needed it to
prevent relapse after prison release
Those reporting the highest injection risks were more
likely to believe OST would be helpful
Bachireddy et al, Drug and Alcohol Dependence 116 (2011) 151–157Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
26.
2. OST ASDRUG TREATMENT
VS
OST AS HIV PREVENTION
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
27.
Opioid Substitution Therapy(OST):
Triple Action
Objective Target population Responsible
sectors, agencies
OST as HIV prevention IDUs Ministry of Health
Prison authorities
NGOs
OST to improve treatment
adherence to ART and TB
DOTS
HIV + IDUs
IDUs with TB
Ministry of Health
ART Centres
Hospitals
Prisons / custodial settings
NGOs
Private Sector
OST as drug dependence
treatment
Opioid dependent persons
(includes both IDUs and
non-injecting drug users)
Ministry of Health
Public Security
Drug treatment and
rehabilitation centres
Prisons / custodial settings
NGOs
Private sector
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
28.
COCKRANE REVIEW: MMT
Methadone is an effective maintenance therapy
intervention for the treatment of heroin dependence
It retains patients in treatment and decreases heroin use
better than treatments that do not utilise opioid
replacement therapy
It does not show a statistically significant superior effect
on criminal activity or mortality
Mattick et al, Cochrane Database Syst Rev. 2009 Jul 8;(3)Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
29.
Impact of MMTProgram, China
In 2008 and 2009, respectively, an
estimated 2969 and 3919 new HIV
infections (excluding secondary
transmission) were prevented
Consumption of heroin was
reduced by 17.0 tons - 22.4 tons
$US939 million - US$1.24 billion in
heroin trade were avoided
MMT program is supported
legislatively and financially by the
central government with multi-
sector cooperation
Incorporation of MMT clinics into
existing medical infrastructure,
which has facilitated delivery of
services
Yin et al, International Journal of Epidemiology 2010;39:ii29–ii37
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
30.
MMT Program, China
(128clinics, 2-year follow-up)
Yin & Wu, 2008:
Presented at 19th International Conference on Harm Reduction,
11-15 May 2008, Barcelona, Spain
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
31.
Components of effectivemethadone
treatment
Flexible but adequate dose of methadone after
stabilisation (usual range 50–150 mg)
Adequate duration of treatment
Goal of maintenance
Rapid and client-centred assessment and induction
Ward et al, 1999. THE LANCET, Vol 353
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
32.
Components of effectivemethadone
treatment
Psychosocial services to deal with social disadvantage
and psychiatric comorbidity
Trained staff with positive attitudes towards MMT and
opioid dependent patients
Affordable - cost of treatment should not exceed ability
to pay
Engagement with clients rather than punishment of
continuing illicit drug use
Ward et al, 1999. THE LANCET, Vol 353
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
33.
Buprenorphine and illicitdrug
use
Fiellin et al, J Acquir Immune Defic Syndr 2011;56:S33–S38Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
34.
OST in HIVsettings:
OST as HIV prevention
Injecting
frequency
Injecting
risks
Sex risks HIV
infectivity
HIV
incidence
OST ↓ ↓ x -- ↓
Adapted from: Degenhardt et al, Lancet 2010; 376: 285–301
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
35.
Evidence for MMTas HIV
prevention
Metzer et al, J Acquir Immune Defic Syndr. 1993 Sep;6(9):1049-56
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
36.
Effectiveness of MMT
MMT is associated with a significant decrease in
injecting drug use and sharing of injecting equipment
MMT is associated with a lower incidence of multiple sex
partners or exchanges of sex for drugs or money, but no
change, or only small decreases, in unprotected sex
Studies of seroconversion, suggest actual reductions in
cases of HIV infection
Farrell et al, International Journal of Drug Policy 16S (2005) S67–S75
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
37.
Evidence for OST:
Otherbenefits in HIV integrated care
BHIVES Collaborative findings
• Established in 10 sites as integrated models of HIV primary care and
substance abuse treatment
• OST with buprenorphine/naloxone potentially effective in improving
health related QOL for HIV-infected patients with concurrent opioid
dependence
• Integration of buprenorphine/naloxone into HIV clinics increases
receipt of high-quality HIV care
• Buprenorphine/naloxone provided in HIV treatment settings also
decreases opioid use
J Acquir Immune Defic Syndr 2011;56Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
38.
Evidence for OSTas HIV prevention:
Buprenorphine in reducing HIV related
risk behaviours
Sullivan et al, J Subst Abuse Treat. 2008; 35(1): 87–92Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
39.
OST medications: Isthere a
choice?
Methadone Buprenorphine
Most researched and proven
effectiveness as HIV prevention and
dependence treatment
Relatively less researched; evidence for
HIV prevention and dependence
treatment exists
Cheaper; cost effective option Expensive
Overdose not uncommon ‘Ceiling effect’ – Safety of the drug
Drug interactions with ARVs – need to
adjust doses
No clinically significant drug
interactions with ARVs
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
40.
Key findings fromWHO
collaborative study on OST and HIV
OST can achieve similar outcomes consistently in a culturally
diverse range of settings in low- and middle-income countries to
those reported widely in high-income countries
It is associated with a substantial reduction in HIV exposure risk
associated with IDU across nearly all the countries
Results support the expansion of opioid substitution treatment
Lawrinson et al, 2008; Addiction, 103, 1484–1492Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
41.
Methadone vs Buprenorphine
Methadone clients have more severe substance abuse and
psychiatric and physical problems compared to buprenorphine
clients
Clients on methadone are more likely to remain in treatment
However, those retained on buprenorphine are more likely to
suppress illicit opiate use and achieve detoxification
Buprenorphine may also recruit more individuals such as those
who do not want methadone to treatment
Pinto et al, J Subst Abuse Treat. 2010;39(4):340-52.
The SUMMIT Trial
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
42.
Effectiveness of OSTwith
methadone or buprenorphine
There is strong evidence that OST with methadone or
buprenorphine suppresses illicit opioid use
Both access to and effectiveness of OST contribute to
sustaining adherence to HAART in HIV-infected IDUs
There is also evidence that OST for HIV-positive IDUs is
associated with improved health outcomes
Farrell et al, International Journal of Drug Policy 16S (2005) S67–S75
Roux et al, 2008; Addiction, 103, 1828–1836Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
43.
Effectiveness of OSTwith
methadone or buprenorphine
Buprenorphine is an effective medication in the
maintenance treatment of heroin dependence, retaining
people in treatment at any dose above 2 mg
Compared to methadone, buprenorphine retains fewer
people when doses are flexibly delivered and at low
fixed doses.
If high doses are used, buprenorphine
and methadone appear no different in effectiveness
care.
Methadone is superior to buprenorphine in retaining
people in treatment
Mattick et al, Cochrane Database Syst Rev. 2014 Feb 6;2
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
44.
3. INTEGRATED OSTSERVICES
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
45.
Integrated Services
Differentmodels of integration
Co-located services
Case management
Referral networks
Role of medical providers in screening and
interventionPresented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
46.
Integrated Services
Differentmodels of integration
Clinic site level integration
Same physician delivering addiction and
medical services
Two physicians working together at the
same clinic
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
47.
Integrated Services
Psychosocialservices
Mental Health Services
Pregnancy and reproductive health services
Infectious diseases care services – HIV, HCV,
TB
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
48.
Integrated Services
Potentialbenefits of providing integrated
substance use and medical care services
Increase drug treatment capacity
Reduce health and administrative costs
Diminish duplication of services
Improve health and drug treatment outcomes
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
49.
New Initiatives atIntegrated
Services
Integrating the Substance use and HIV
services
Buprenorphine HIV Evaluation and Support
Services (BHIVES)
Integration into community and hospital based
clinics
Weiss et al, J Acquir Immune Defic Syndr Volume 56, Supp 1, March 2011
BHIVES Collaborative
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
50.
Evidence for OST:
PositiveHIV treatment outcomes
Altice et al, J Acquir Immune Defic Syndr Volume 56, Supp 1, March 2011
BHIVES Collaborative
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
51.
Reasons for pooradherence to
OST and ART
Perception of adverse effects
Alcohol consumption
Depression
Roux et al, 2008; Addiction, 103, 1828–1836Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
52.
Integration with mentalhealth
services
High prevalence of personality disorders
Depression
Co-morbid substance use disorders
Integrated services
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
53.
OST, Pregnancy and
Neonatalabstinence syndrome
Methadone has been the recommended standard of care for
opioid-dependent pregnant women
Buprenorphine is an alternative to methadone for the treatment
of opioid dependency during pregnancy
The benefits of buprenorphine in reducing the severity of NAS
among neonates with this complication suggest that it should
be considered a first-line treatment option in pregnancy
Jones et al, N Engl J Med 2010; 363:2320-31Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
54.
How to improveand ensure effective
linkages?
Co-location of services
Collaboration between various departments
Cross training of health professionals
Treatment literacy for IDUs
Other supportive services
mental health, psychosocial support, nutrition
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
55.
4. KEY GAPSIN OST PROGRAM IMPLEMENTATION
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
56.
OST adoption
Despiteevidence, detoxification is preferred than opioid
substitution therapy by several addiction programs
Leadership qualities critical to OST adoption
Leaders’ training treatment orientation, tenure determine
OST adoption
Leaders less ideologically grounded in abstinence only
approaches
Friedmann et al, J Behav Heal Serv Res 2010, 37(3):322-37Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
57.
OST: Key challengesfor the
resource poor settings
What is the most effective model for implementing
OST?
How can OST become a fundamental component of
integrated HIV prevention?
How can the quality of the OST programmes be
ensured and evaluated?
Kermode, Crofts, Kumar & Dorabjee, Bull World Health Organ 2011;89:243
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
58.
Efficient ways ofdelivering opioid
substitution medication
Prescription by general practitioners
Community pharmacies
Community based approach to OST
Integration into primary care
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
59.
Key obstacles tosafe and effective
delivery of opioid substitution medication
Restricted Government funding and support for
OST
Limited patient capacity to pay for OST
Prejudices against OST
A balance between overregulation and laissez-
faire provision
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
60.
Advocacy in IslamicRepublic of Iran
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
61.
Islamic Republic ofIRAN
This order is to remind judges at all courts of justice and
prosecutors’ offices throughout the country that, since a major
element of criminal action is verifiable malicious intent, the
aforementioned interventions are clearly void of such intent and,
instead, are motivated by the will to protect society from the
spread of deadly contagious diseases, such as AIDS and hepatitis.
Therefore all judicial authorities must consider the lack of
malicious intent in the interventions of the Ministry of Health and
Medical Education as well as those of other centres and
organizations that are active in this field. They must not accuse
service providers of assisting in the criminal abuse of narcotics
and must not impede the implementation of such needed and
beneficial programmes. Seyed Mahmood Hashemi Sharoudi
Head of the Judiciary
24 January 2005
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
62.
Policy and OST
Policy shifts increase coverage of OST
In Vietnam, Malaysia and China, shift from punitive
law enforcement to evidence based treatment has
increased coverage
Policy shift in Ukraine increased OST coverage
Russia’s stand against OST and closing down
access to information on methadone
Degenhart et al, Int J Drug Policy 2014; 25(1):53-60
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
63.
Workforce and Training
Limited training and teaching in addiction
medicine during MBBS
Possibility for one day training course for
prescribing buprenorphine
Training of nurses, pharmacists and other
healthcare workers
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
64.
MMT in China:Barriers and
facilitators
Barriers to MMT for
clients
Requirement for registration in the police department
Perceived societal stigma; Logistic difficulties;
Side effects; Inappropriate perception of methadone;
Fear of being addicted to another drug;
Lack of additional services; Economic burden
Barriers for Service
Providers in MMT
Financial difficulties; Lack of professional training
Difficulties in pursuit of career; Lack of institutional
support
Concern for personal safety; Low income
Large work load; Misunderstanding by society
Factors associated
with successful MMT
MMT clinics affiliated with local CDCs have more clients,
higher retention rates
Longer operating hours
Incentives for compliant clients
Lin et al, J Subst Abuse Treat. 2010; 38(2): 119.
Lin et al, Int J Drug Policy. 2010; 21(3): 173–178
Lin, 2009. Dissertations & Theses, UCLA
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
65.
Factors that maximise
participationin OST programs
Client related Ease of access
Extended opening hours at clinics
Sufficiently high doses
Service Providers
related
Non-judgemental clinicians
Professionally & technically competent to deal with
addiction related issues
High staff morale
Access to allied medical, psychological and welfare
services
Support related Significant peer support
Family support
Support groups
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
66.
OST: Key gapsidentified
• OST is available for a limited number of IDUs at present in
most countries of South Asia
• Lack of exclusive OST centres for women injecting drug
users
• Effective linkages with other services such as ICTC, ART,
TB DOTS, Drug dependence treatment is a significant
challenge
• Pharmacological options for OST need to be expanded
– Methadone; Buprenorphine; Buprenorphine-Naloxone; Oral morphine
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
67.
Evidence for OSTas HIV prevention:
Coverage is critical
Country IDU
prevalence
(%)
OST
availability
HIV
incidence
among
IDUs, 2005
HIV
incidence
among
IDUs, 2006
Russian
Federation
Current IDU
1.78
OST not available 72/million 79/million
Ukraine Current IDU
1.16 (1.00, 1.31)
OST mostly
unavailable (~1%)
134/million 153/million
USA Current IDU
0.96 (0.67, 1.34)
OST available
(1998–2004:
15%–25%)
18/million NA
Canada Lifetime IDU
1.3 (1.0, 1.7)
OST available
(2003: ~26%)
7.2/million 7.3/million
EU (27 countries) Current IDU
0.19 (0.16–0.21)
OST available
(2004: ~33%)
6.4/million 5.9/million
Australia Current IDU
1.09 (0.65–1.50)
OST available
(2006: ~50%)
1.6/million 1.4/million
Weissing et al, Am J Public Health 2009; 99:1049–1052.
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
68.
Why OST isneeded for non-injecting
opioid dependent users?
Strathdee et al, Lancet 2010; 376: 268–84
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
69.
5. CONCLUSION
Presented atthe national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi
70.
Conclusion
• OST isan effective evidence based drug use treatment for injecting
as well as non-injecting opioid dependent individuals
• OST is evidence based opioid use disorder treatment
• OST in HIV settings is primarily to prevent HIV and improve ART
adherence; often benefits go beyond HIV related issues
• Integrated OST services are essential
• The identified gaps in OST in Asia can be effectively addressed in
future through scaled-up efforts (in community & custodial settings)
and multi-sectoral collaboration
Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi